This HTML5 document contains 82 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n18http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/iuphar/
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/guide-to-pharmacology/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/national-drug-code-directory/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/drugbank/drug/DB00844/identifier/chebi/
n17http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00844
rdf:type
n5:Drug
n5:description
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
n5:dosage
n21:271B4B32-363D-11E5-9242-09173F13E4C5 n21:271B4B33-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10534607
n5:group
approved
n5:halfLife
The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
n5:indication
For the relief of moderate to severe pain.
owl:sameAs
n14:DB00844 n18:DB00844
dcterms:title
Nalbuphine
adms:identifier
n4:7454 n16:PA164745372 n19:Nalbuphine n22:1663 n23:1663 n24:DB00844 n25:0555-1121-05 n26:C07251 n27:D08246
n5:mechanismOfAction
The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.
n5:packager
n10:271B4B28-363D-11E5-9242-09173F13E4C5 n10:271B4B29-363D-11E5-9242-09173F13E4C5 n10:271B4B26-363D-11E5-9242-09173F13E4C5 n10:271B4B27-363D-11E5-9242-09173F13E4C5 n10:271B4B25-363D-11E5-9242-09173F13E4C5 n10:271B4B2C-363D-11E5-9242-09173F13E4C5 n10:271B4B2A-363D-11E5-9242-09173F13E4C5 n10:271B4B2B-363D-11E5-9242-09173F13E4C5 n10:271B4B23-363D-11E5-9242-09173F13E4C5 n10:271B4B24-363D-11E5-9242-09173F13E4C5
n5:synonym
Nalbufina Nalbuphine N-Cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriol Nalbuphin Nalbuphinum
n5:toxicity
Oral, acute LD50 is 1100 mg/kg in dog. Symptoms of overdose include primarily sleepiness and mild dysphoria.
n8:hasAHFSCode
n9:28-08-12
n5:proteinBinding
Not appreciably bound.
n5:salt
n5:synthesisReference
Michael R. Magruder, "Nalbuphine-narcotic analgesic composition and method of producing analgesia." U.S. Patent US4366159, issued August, 1981.
foaf:page
n12:nalbuphine.htm n20:nalbuphine.html
n5:IUPAC-Name
n7:271B4B38-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B4B3E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B4B3D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B4B3A-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B4B3B-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B4B3C-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B4B4E-363D-11E5-9242-09173F13E4C5 n7:271B4B36-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B4B50-363D-11E5-9242-09173F13E4C5 n7:271B4B34-363D-11E5-9242-09173F13E4C5 n7:271B4B37-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B4B35-363D-11E5-9242-09173F13E4C5
n5:pKa
n7:271B4B51-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n17:N02AF02
n5:H-Bond-Acceptor-Count
n7:271B4B44-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B4B45-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B4B3F-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B4B40-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B4B42-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B4B41-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B4B43-363D-11E5-9242-09173F13E4C5
n5:absorption
The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
20594-83-6
n5:containedIn
n6:271B4B31-363D-11E5-9242-09173F13E4C5 n6:271B4B2F-363D-11E5-9242-09173F13E4C5 n6:271B4B30-363D-11E5-9242-09173F13E4C5 n6:271B4B2D-363D-11E5-9242-09173F13E4C5 n6:271B4B2E-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n7:271B4B4A-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B4B4C-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B4B4D-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B4B4F-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B4B49-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B4B48-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B4B4B-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B4B39-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B4B46-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B4B47-363D-11E5-9242-09173F13E4C5